Krystal Biotech COO Buys 12,500 Shares at $63 – A Bold Insider Bet on Gene‑Therapy Growth.
Krystal Biotech insider buying at $63.55 shows long‑term confidence amid FDA RMAT approval and volatile market, hinting at potential upside for investors.
4 minutes to read